Launching a drug development company with novel technology from academia
Our corporate group has worked with hundreds of entrepreneurs at this stage to help them optimally and efficiently select and form the appropriate legal entity
The Faber Difference
Values & Community
Our Clients
Areas of Expertise
Launching a drug development company with novel technology from academia
Our corporate group has worked with hundreds of entrepreneurs at this stage to help them optimally and efficiently select and form the appropriate legal entity
Getting ready for a global Phase 2 or 3 clinical trial
Our experienced contracts specialists work alongside attorneys steeped in the business side of life sciences
Establishing a pharmaceutical supply chain
Our team of professionals understands the industry-specific drivers of complex supply chains
The Faber Difference
Values & Community
Our Clients
Areas of Expertise
Launching a drug development company with novel technology from academia
Our corporate group has worked with hundreds of entrepreneurs at this stage to help them optimally and efficiently select and form the appropriate legal entity
Getting ready for a global Phase 2 or 3 clinical trial
Our experienced contracts specialists work alongside attorneys steeped in the business side of life sciences
Establishing a pharmaceutical supply chain
Our team of professionals understands the industry-specific drivers of complex supply chains
Event
The ACI’s 9th Annual Summit on Women Leaders in Life Sciences Law will be held July 27th – July 28th in Boston, MA. The conference provides a forum for in-person networking and collaboration, with the opportunity to learn from nearly 200 female attorneys and executives from the biotech, pharmaceutical, and medical device industries.
On July 28th, Faber Principal Lily Vakili will participate in the panel Broadening Your Horizons: Key International Developments Impacting the Global Life Sciences Industry. She will be joined by Donna Meuth, Associate General Counsel of Intellectual Property at Eisai, and Deirdre Parsons, Senior Director, Global Public Policy & Government Relations at Alnylam Pharmaceuticals.